⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405606 | 1.00 | — | — | |
| SCHEMBL23405638 | 1.00 | — | — | |
| SCHEMBL3954628 | 0.87 | TP53 (0.43) | — | |
| SCHEMBL19012037 | 0.87 | TP53 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4430190 | 0.85 | KDM4E (0.45) | — | |
| SCHEMBL25898496 | 0.84 | — | — | |
| SCHEMBL517143 | 0.77 | — | — | |
| SCHEMBL4065197 | 0.77 | — | — | |
| SCHEMBL517144 | 0.77 | — | — | |
| SCHEMBL25898495 | 0.75 | GABRP (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9409866-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20150344429-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| EP-1940788-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| CN-1976915-A | HIV integrase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |